Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Fish and Richardson
Queensland Health
Chinese Patent Office
Medtronic
McKinsey

Generated: September 18, 2019

DrugPatentWatch Database Preview

INVOKANA Drug Profile

  Try a free trial


See Plans and Pricing

« Back to Dashboard

When do Invokana patents expire, and when can generic versions of Invokana launch?

Invokana is a drug marketed by Janssen Pharms and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and sixteen patent family members in forty-four countries.

The generic ingredient in INVOKANA is canagliflozin. There are twenty-one drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the canagliflozin profile page.

Drug patent expirations by year for INVOKANA
Generic Entry Opportunity Date for INVOKANA
Generic Entry Date for INVOKANA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Medical Subject Heading (MeSH) Categories for INVOKANA
Synonyms for INVOKANA
(1S)-1,5-Anhydro-1-(3-((5-(4-fluorophenyl)-2-thienyl)methyl)-4-methylphenyl)-D-glucitol
(1S)-1,5-Anhydro-1-(3-((5-(4-fluorophenyl)-2-thienyl)methyl)-4-methylphenyl)-D-glucitol hemihydrate
(1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methyl-phenyl)-D-glucitol
(1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucitol
(1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucitol--water (2/1)
(1s)-1,5-anhydro-1-c-(3-((5-(4-fluorophenyl)-2-thienyl)methyl)-4-methylphenyl)-d-glucitol
(1S)-1,5-Anhydro-1-C-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-D- glucitol hemihydrate
(1S)-1,5-Anhydro-1-c-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-D-glucitol
(1S)-1,5-Anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol
(1S)-1,5-Anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol hydrate (2:1)
(2S,3R,4R,5S,6R)-2-(3-((5-(4-FLUOROPHENYL)THIOPHEN-2-YL)METHYL)-4-METHYLPHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL
(2S,3R,4R,5S,6R)-2-(3-((5-(4-Fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol hemihydrate
(2S,3R,4R,5S,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol hydrate(2:1)
(2S,3R,4R,5S,6R)-2-(3-{[5-(4-fluorophenyl)thiophen-2-yl]methyl}-4-methylphenyl)-6-(hydroxymethyl)oxane-3,4,5-triol
0SAC974Z85
1-(beta-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene
6S49DGR869
842133-18-0
928672-86-0
ABP000358
AC-26303
AC-29556
ACN-034470
AJ-108287
AK198969
AKOS025401827
AKOS026674130
API0013707
BC638828
BCP9000477
BCPP000303
BDBM50386885
C24H25FO5S
Cagliflozin hemihydrate
Canagliflozin
Canagliflozin (USAN/INN)
Canagliflozin [INN]
Canagliflozin [USAN:INN]
Canagliflozin anhydrous
canagliflozin hemihydrate
Canagliflozin hydrate
Canagliflozin hydrate (JAN)
Canagliflozin/
CC0249
CCG-229581
CHEBI:73272
CHEBI:73274
CHEMBL2048484
CHEMBL2103841
CS-0522
D-Glucitol, 1,5-anhydro-1-C-(3-((5-(4-fluorophenyl)-2-thienyl)methyl)-4- methylphenyl)-, (1S)-
D-glucitol, 1,5-anhydro-1-c-(3-((5-(4-fluorophenyl)-2-thienyl)methyl)-4- methylphenyl)-, (1s)-
D-Glucitol, 1,5-anhydro-1-C-(3-((5-(4-fluorophenyl)-2-thienyl)methyl)-4-methylphenyl)-, hydrate (2:1), (1S)-
D-Glucitol, 1,5-anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-, (1S)-
D09592
DB08907
FT-0664217
FT-0699228
GLU008
GTPL4582
HSDB 8284
HY-10451
Invokana (TN)
J-500391
JNJ 24831754
JNJ 24831754AAA
JNJ 24831754ZAE
JNJ 28431754
JNJ-24831754-ZAE
JNJ-28431754
JNJ-28431754-AAA
KB-271653
KB-75871
KS-1443
MLS006011126
MolPort-021-804-941
MolPort-042-663-494
PB22925
Q-4516
RL05180
s2760
SCHEMBL157162
SCHEMBL681039
SMR004702906
SW219119-1
TA 7284
TA-7284
Tube102
UNII-0SAC974Z85
UNII-6S49DGR869
VHOFTEAWFCUTOS-TUGBYPPCSA-N
XTNGUQKDFGDXSJ-ZXGKGEBGSA-N
Y0287
ZINC43207238

US Patents and Regulatory Information for INVOKANA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms INVOKANA canagliflozin TABLET;ORAL 204042-001 Mar 29, 2013 RX Yes No   Try a Free Trial   Try a Free Trial Y Y   Try a Free Trial
Janssen Pharms INVOKANA canagliflozin TABLET;ORAL 204042-002 Mar 29, 2013 RX Yes Yes   Try a Free Trial   Try a Free Trial   Try a Free Trial
Janssen Pharms INVOKANA canagliflozin TABLET;ORAL 204042-001 Mar 29, 2013 RX Yes No   Try a Free Trial   Try a Free Trial Y Y   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for INVOKANA
Drugname Dosage Strength RLD Date
➤ Subscribe Tablets 100 mg and 300 mg ➤ Subscribe   Try a Free Trial

Supplementary Protection Certificates for INVOKANA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1651658 C20140011 00102 Estonia   Try a Free Trial PRODUCT NAME: KANAGLIFLOSIIN;REG NO/DATE: K(2013)8171 (LOPLIK) 15.11.2013
1651658 14C0034 France   Try a Free Trial PRODUCT NAME: CANAGLIFLOZINE; REGISTRATION NO/DATE: EU/1/13/884/001-008 20131115
1651658 29/2014 Austria   Try a Free Trial PRODUCT NAME: CANAGLIFLOZIN; REGISTRATION NO/DATE: EU/1/13/884 20131115
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
McKesson
Citi
Accenture
US Department of Justice
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.